The first edition of Science for health was held in the heart of Brussels on 11th September 2019 with a focus on cell therapy. The event attracted over 300 researchers, clinicians and industry professionals active in the the local or international cell therapy ecosystem. Top-speakers provided interesting insights into the current state of cell therapy in Belgium, as well as requirements for further progress. Collaboration, especially outside of the traditional partnerships, is key.
Last month, Galapagos sealed a 5-billion-dollar deal with Gilead. Now that the dust has started to settle, we’re taking a closer look at the agreement. Why is this deal so unique in the biotech world? What will the ripple effects be in the European ecosystem? BioVox spoke with Lenny Van Steenhuyse, Healthcare Equity Analyst at KBC Securities, for a deeper insight.
Franz-Ulrich Hartl and Arthur Horwich have been named the winners of the 2019 Dr. Paul Janssen Award for Biomedical Research. The award will be granted for their revolutionary insights into chaperone-mediated protein folding, a key process for biological function. The winners will share their insights during the annual award ceremony, which will be celebrated both at the Janssen Beerse Campus in Belgium on September 27 and at the New York Academy of Sciences in the US on October 3, providing attendees with a unique opportunity to meet two of the world’s leading scientists.
Collaboration is vital for science. Without cross-pollination of ideas and talent, progress would be excruciatingly slow in both industry and academia. Networking opportunities, like the annual Knowledge for Growth event and Science for health, stimulate research collaboration by connecting people. So, what’s the role of a cluster organization in all this? BioVox spoke with flanders.bio representatives Pascale Engelen and Katrien Lorré to find out.
The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags of more than a million dollars per treatment. Is the pharma industry recklessly overstepping a line here, or do they fall within current standards of value-based drug pricing? With more of these drugs soon to be rolling out of pharma pipelines, the stakes are rising high for patients, industry, governments, health insurance companies, as well as investors. It all warrants a deeper dive into the case.
Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science for health event in September the visionary Christian Homsy, former Celyad CEO, will be presenting one of the keynote talks. In this BioVox interview, we asked him to share his thoughts on the challenges faced by a company that’s pushing boundaries in the oncology space.
Food waste is a major global issue exacerbated by premature fruit spoilage. A US company, StixFresh, is working together with VIB-KU Leuven Prof Patrick Van Dijck to develop a solution to the problem. The company has created stickers coated in a plant-based antimicrobial formula that protects fruit from fungal infections, extending their shelf life by several weeks.
The first edition of Science for health was held in the heart of Brussels on 11th September 2019 with a focus on cell therapy. The event attracted over 300 researchers, clinicians and industry professionals active in the the local or international cell therapy ecosystem. Top-speakers provided interesting insights into the current state of cell therapy in Belgium, as well as requirements for further progress. Collaboration, especially outside of the traditional partnerships, is key.
Last month, Galapagos sealed a 5-billion-dollar deal with Gilead. Now that the dust has started to settle, we’re taking a closer look at the agreement. Why is this deal so unique in the biotech world? What will the ripple effects be in the European ecosystem? BioVox spoke with Lenny Van Steenhuyse, Healthcare Equity Analyst at KBC Securities, for a deeper insight.
Franz-Ulrich Hartl and Arthur Horwich have been named the winners of the 2019 Dr. Paul Janssen Award for Biomedical Research. The award will be granted for their revolutionary insights into chaperone-mediated protein folding, a key process for biological function. The winners will share their insights during the annual award ceremony, which will be celebrated both at the Janssen Beerse Campus in Belgium on September 27 and at the New York Academy of Sciences in the US on October 3, providing attendees with a unique opportunity to meet two of the world’s leading scientists.
Collaboration is vital for science. Without cross-pollination of ideas and talent, progress would be excruciatingly slow in both industry and academia. Networking opportunities, like the annual Knowledge for Growth event and Science for health, stimulate research collaboration by connecting people. So, what’s the role of a cluster organization in all this? BioVox spoke with flanders.bio representatives Pascale Engelen and Katrien Lorré to find out.
The newest generation of ground-breaking gene therapy drugs, Zolgensma and Zynteglo, come with eye-catching price tags of more than a million dollars per treatment. Is the pharma industry recklessly overstepping a line here, or do they fall within current standards of value-based drug pricing? With more of these drugs soon to be rolling out of pharma pipelines, the stakes are rising high for patients, industry, governments, health insurance companies, as well as investors. It all warrants a deeper dive into the case.
Belgian company Celyad is a trailblazer in oncology: its T cell therapies based on NK receptors are cutting edge even for CAR-T. At the Science for health event in September the visionary Christian Homsy, former Celyad CEO, will be presenting one of the keynote talks. In this BioVox interview, we asked him to share his thoughts on the challenges faced by a company that’s pushing boundaries in the oncology space.
Food waste is a major global issue exacerbated by premature fruit spoilage. A US company, StixFresh, is working together with VIB-KU Leuven Prof Patrick Van Dijck to develop a solution to the problem. The company has created stickers coated in a plant-based antimicrobial formula that protects fruit from fungal infections, extending their shelf life by several weeks.